Literature DB >> 3257663

Selective delivery of pentamidine to the lung by aerosol.

A B Montgomery1, R J Debs, J M Luce, K J Corkery, J Turner, E N Brunette, E T Lin, P C Hopewell.   

Abstract

In 8 patients with diffuse infiltrates on chest radiograph undergoing fiberoptic bronchoscopy for suspected Pneumocystis carinii pneumonia, bronchoalveolar lavage sediment and supernatant concentrations of pentamidine were compared 18 to 24 h after administration of 4 mg/kg intravenous (n = 3) and aerosolized (n = 5) pentamidine isethionate. Aerosol was inhaled for 35 to 40 min with 300 mg of pentamidine isethionate in a jet nebulizer, baffled to decrease the particle size to 1.42 micron +/- 1.88 (mass median aerodynamic diameter +/- geometric standard deviation). Bronchoalveolar pentamidine concentrations were: In sediment, 9.34 +/- 1.74 postintravenous versus 705 +/- 242 ng/ml postaerosol (mean +/- SEM, p less than 0.05); supernatant, 2.64 +/- 0.73 postintravenous versus 23.2 +/- 7.75 ng/ml postaerosol (mean +/- SEM, p less than 0.05). Serum pentamidine levels were low or undetectable after aerosolization. Aerosol administration delivers significantly higher concentrations of pentamidine to the air spaces than does intravenous delivery in patients with diffuse alveolar infiltrates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257663     DOI: 10.1164/ajrccm/137.2.477

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Efficacy and effects on pulmonary function tests of weekly 600 mg aerosol pentamidine as prophylaxis against Pneumocystis carinii pneumonia.

Authors:  E L Ong; E M Dunbar; B K Mandal
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

Review 2.  Disseminated Pneumocystis carinii in a patient receiving aerosolized pentamidine prophylaxis.

Authors:  S M Berman; B Shah; F A Wyle; M Dacosta-Iyer; D M McRae
Journal:  West J Med       Date:  1990-07

Review 3.  Aerosol deposition in the alveolar space.

Authors:  G Huchon
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 4.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

5.  Alteration of the natural history of Pneumocystis carinii infection in patients with acquired immunodeficiency syndrome receiving aerosolized pentamidine.

Authors:  D M Kates; T G Sparling; N Jetha; D R Burdge
Journal:  West J Med       Date:  1991-06

6.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 7.  Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

Authors:  J P Monk; P Benfield
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 8.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

9.  Nebulised pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  R F Miller; P Godfrey-Faussett; S J Semple
Journal:  Thorax       Date:  1989-07       Impact factor: 9.139

Review 10.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.